Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone510-742-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.73 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc (NASDAQ:RVNC) announced its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.95) by $0.17. Revance Therapeutics had a negative net margin of 3,824.22% and a negative return on equity of 73.66%. View Revance Therapeutics' Earnings History.
When is Revance Therapeutics' next earnings date?
What price target have analysts set for RVNC?
10 analysts have issued 12-month price objectives for Revance Therapeutics' stock. Their predictions range from $17.83 to $50.00. On average, they anticipate Revance Therapeutics' stock price to reach $37.8538 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.
What is the consensus analysts' recommendation for Revance Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (3/14/2019)
- 2. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for early-stage biotechs. Rather, we believe value lies in clinical assets and development. Revance remains on track to file a BLA for DAXI (RT002) in 1H19 and we anticipate a product launch in 2H20. We continue to see significant value in the company’s manufacturing assets, which have led to important collaboration deals. 2019 equity offering, Revance should have sufficient cash to get through most of 2020. $37 PT." (2/27/2019)
- 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)
- 4. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $50 on shares of RVNC. We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive the stock higher. RVNC’s long-duration, next-generation injectable neuromodulator may be a pipeline in a product. RT002 targets a $3B+ market opportunity for both medical and aesthetic indications." (11/1/2018)
Has Revance Therapeutics been receiving favorable news coverage?
Media headlines about RVNC stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Revance Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include MorphoSys (MOR), Enerplus (ERF), Quidel (QDEL), Mirati Therapeutics (MRTX), MEDNAX (MD), Akcea Therapeutics (AKCA), The Ensign Group (ENSG), ConvaTec Group (CTEC), Repligen (RGEN), Acadia Healthcare (ACHC), Glaukos (GKOS), Emergent Biosolutions (EBS), Dechra Pharmaceuticals (DPH), LifePoint Health (LPNT) and Aphria (APHA).
What other stocks do shareholders of Revance Therapeutics own?
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 57)
- Dr. Abhay Joshi, Chief Operating Officer (Age 56)
- Mr. Tobin C. Schilke, Chief Financial Officer (Age 44)
- Mr. Cyril Allouche, Chief Accounting Officer & Corp. Controller (Age 47)
- Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
Who are Revance Therapeutics' major shareholders?
Revance Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.67%), Bank of New York Mellon Corp (6.87%), Northern Trust Corp (1.16%), Millennium Management LLC (1.06%), Geode Capital Management LLC (1.04%) and Geode Capital Management LLC (1.04%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.
Which major investors are selling Revance Therapeutics stock?
RVNC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Bank of America Corp DE, First Midwest Bank Trust Division, Principal Financial Group Inc., Barclays PLC, Northern Trust Corp and Rhenman & Partners Asset Management AB. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche, L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.
Which major investors are buying Revance Therapeutics stock?
RVNC stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Candriam Luxembourg S.C.A., California Public Employees Retirement System, Geode Capital Management LLC, Geode Capital Management LLC and MFN Partners Management LP. View Insider Buying and Selling for Revance Therapeutics.
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $15.97.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $703.14 million and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis.
What is Revance Therapeutics' official website?
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
